Device Ophthalmology

Precision7

Payments companies reported to CMS as associated with Precision7. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$2.3Massociated payments (2023-2025)

13,402clinicians with associated payments

2companies reporting

By year

2025 $2.3M

Payments reported as associated with Precision7, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Optometrist $2.2M

Corneal and Contact Management $69K

Ophthalmology $6,967

Vision Therapy $4,003

Pediatrics (Optometrist) $2,380

Occupational Vision $1,758

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Precision7

These are the largest totals companies reported as associated with Precision7. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

Clinician	Location	Specialty	Associated payments (2023-2025)
Jason Compton	New York, NY	Optometrist	$100,076.96
Sanjay Patel	Apex, NC	Optometrist	$87,965.35
April Jasper	West Palm Beach, FL	Optometrist	$83,874.91
Jessilin Quint	Chicago, IL	Optometrist	$70,916.59
Claudio Lagunas	Houston, TX	Optometrist	$58,057.16
Susan Resnick	New York, NY	Optometrist	$54,146.41
Aaron Luekenga	Santa Paula, CA	Optometrist	$33,938.45
Britt Gustafson	Eden Prairie, MN	Optometrist	$33,809.48
Joseph Allen	Richmond, VA	Optometrist	$32,173.79
Glenda Moheeputh	Pembroke Pines, FL	Optometrist	$31,151.52

Prescribed Precision7?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

What this means, and what it doesn't

These payments are legal and common. Drug and device makers routinely pay for meals at educational events, consulting, speaking, travel, and research. Companies are required by federal law to report them; that's why this data exists.
A payment is not evidence of wrongdoing. Most clinicians who accept industry payments provide excellent care. Research payments in particular often reflect participation in clinical trials.
Context beats raw numbers. A few hundred dollars in sandwiches over several years is typical. What's worth understanding is scale, source, and purpose, which is what this page shows.
The data comes from companies, not doctors. Figures are "as reported to CMS" by the paying companies. Clinicians can dispute records through CMS's official process.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.